ICU length of stay (selenium) · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
Length of hospital stay · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
Adverse events · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
Treatment failure · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
It is very uncertain whether summary of findings table ‐ High flow nasal cannula (HFNC) changes treatment failure compared with continuous positive airway pressure (CPAP) (very low certainty).
1 finding from 1 review
Chronic lung disease · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
Duration of any form of respiratory support (any form of non‐invasive respiratory support with or without supplemental oxygen) · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
ICU length of stay (general intensive care patients) · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
Adverse events ‐ nasal trauma · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
It is very uncertain whether summary of findings table ‐ High flow nasal cannula (HFNC) changes adverse events ‐ nasal trauma compared with continuous positive airway pressure (CPAP) (very low certainty).
1 finding from 1 review
Adverse events ‐ abdominal overdistention · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
It is very uncertain whether summary of findings table ‐ High flow nasal cannula (HFNC) changes adverse events ‐ abdominal overdistention compared with continuous positive airway pressure (CPAP) (very low certainty).
1 finding from 1 review
Death · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
Treatment failure · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
Summary of findings table ‐ High flow nasal cannula (HFNC) may leads to lower treatment failure compared with low flow nasal cannula (LFNC) (low certainty).
1 finding from 1 review
Circuit lifespana · AKI patients receiving CKRT
1 finding from 1 review
Death from any cause at day 28 of · AKI patients receiving CKRT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recovery of kidney function · AKI patients receiving CKRT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Vascular access complications · AKI patients receiving CKRT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Event‐free survival · children, adolescents, and young adults with primary metastatic Ewing sarcoma
High‐dose chemotherapy followed by autologous haematopoietic cell… showed no clear difference in event‐free survival (reported as number of participants with… compared with conventional chemotherapy plus whole lung irradiation (low certainty).
1 finding from 1 review
Overall survival · children, adolescents, and young adults with primary metastatic Ewing sarcoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality‐adjusted survival · children, adolescents, and young adults with primary metastatic Ewing sarcoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Toxicity · children, adolescents, and young adults with primary metastatic Ewing sarcoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression‐free survival · children, adolescents, and young adults with primary metastatic Ewing sarcoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found